While aromatase suppression has been associated with increased risk for AD as summarized above, meta-analyses have been inconclusive about potential sex differences (Roselli et al., 1998; Medway et al., 2014; Prange-Kiel et al., 2016). Here, CYP19A1 is linked to Alzheimer disease.